Global Radiopharmaceuticals in Nuclear Medicine Market Research Report 2024(Status and Outlook)

Global Radiopharmaceuticals in Nuclear Medicine Market Research Report 2024(Status and Outlook)



Report Overview: Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases. Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide. The Global Radiopharmaceuticals in Nuclear Medicine Market Size was estimated at USD 5225.65 million in 2023 and is projected to reach USD 7002.88 million by 2029, exhibiting a CAGR of 5.00% during the forecast period. This report provides a deep insight into the global Radiopharmaceuticals in Nuclear Medicine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Radiopharmaceuticals in Nuclear Medicine Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market. In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Radiopharmaceuticals in Nuclear Medicine market in any manner. Global Radiopharmaceuticals in Nuclear Medicine Market: Market Segmentation Analysis The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments. Key Company Bracco Imaging S.P.A. Cambridge Isotope Laboratories, Inc. Cardinal Health, Inc. Covidien, Plc Eczacibasi-Monrol Fujifilm Holdings Corporation GE Healthcare (Subsidiary Of General Electric Company) IBA Group Isotec, Inc. (Sigma-Aldrich) Lantheus Medical Imaging, Inc. Nordion, Inc. Ntp Radioisotopes (Pty), Ltd. Siemens Healthcare (Subsidiary Of Siemens AG) Taiyo Nippon Sanso Corporation Urenco Limited Rotem Industries, Ltd., Inc. Australian Nuclear Association And Technology Organization (ANSTO) Board of Radiation And Isotope Technology (BRIT) Institute of Atomic Energy Polatom Radioisotope Centre Institute of Isotopes Co., Ltd. Institute Of Radioelement (IRE) Market Segmentation (by Type) Diagnostic Radiopharmaceuticals Therapy Radiopharmaceuticals Enriched Stable Isotopes Market Segmentation (by Application) Diagnostic Application Therapeutic Application Research Pharmaceutical Other Geographic Segmentation • North America (USA, Canada, Mexico) • Europe (Germany, UK, France, Russia, Italy, Rest of Europe) • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific) • South America (Brazil, Argentina, Columbia, Rest of South America) • The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA) Key Benefits of This Market Research: • Industry drivers, restraints, and opportunities covered in the study • Neutral perspective on the market performance • Recent industry trends and developments • Competitive landscape & strategies of key players • Potential & niche segments and regions exhibiting promising growth covered • Historical, current, and projected market size, in terms of value • In-depth analysis of the Radiopharmaceuticals in Nuclear Medicine Market • Overview of the regional outlook of the Radiopharmaceuticals in Nuclear Medicine Market: Key Reasons to Buy this Report: • Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change • This enables you to anticipate market changes to remain ahead of your competitors • You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents • The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly • Provision of market value (USD Billion) data for each segment and sub-segment • Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market • Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region • Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled • Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players • The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions • Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis • Provides insight into the market through Value Chain • Market dynamics scenario, along with growth opportunities of the market in the years to come • 6-month post-sales analyst support Customization of the Report In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met. Note: this report may need to undergo a final check or review and this could take about 48 hours. Chapter Outline Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods. Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Radiopharmaceuticals in Nuclear Medicine Market and its likely evolution in the short to mid-term, and long term. Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market. Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis. Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc. Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years. Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years. Chapter 12 is the main points and conclusions of the report.


1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Radiopharmaceuticals in Nuclear Medicine
1.2 Key Market Segments
1.2.1 Radiopharmaceuticals in Nuclear Medicine Segment by Type
1.2.2 Radiopharmaceuticals in Nuclear Medicine Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Radiopharmaceuticals in Nuclear Medicine Market Overview
2.1 Global Market Overview
2.1.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Radiopharmaceuticals in Nuclear Medicine Market Competitive Landscape
3.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Manufacturers (2019-2024)
3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Manufacturers (2019-2024)
3.3 Radiopharmaceuticals in Nuclear Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Radiopharmaceuticals in Nuclear Medicine Sales Sites, Area Served, Product Type
3.6 Radiopharmaceuticals in Nuclear Medicine Market Competitive Situation and Trends
3.6.1 Radiopharmaceuticals in Nuclear Medicine Market Concentration Rate
3.6.2 Global 5 and 10 Largest Radiopharmaceuticals in Nuclear Medicine Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Radiopharmaceuticals in Nuclear Medicine Industry Chain Analysis
4.1 Radiopharmaceuticals in Nuclear Medicine Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Radiopharmaceuticals in Nuclear Medicine Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Radiopharmaceuticals in Nuclear Medicine Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2019-2024)
6.3 Global Radiopharmaceuticals in Nuclear Medicine Market Size Market Share by Type (2019-2024)
6.4 Global Radiopharmaceuticals in Nuclear Medicine Price by Type (2019-2024)
7 Radiopharmaceuticals in Nuclear Medicine Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Radiopharmaceuticals in Nuclear Medicine Market Sales by Application (2019-2024)
7.3 Global Radiopharmaceuticals in Nuclear Medicine Market Size (M USD) by Application (2019-2024)
7.4 Global Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate by Application (2019-2024)
8 Radiopharmaceuticals in Nuclear Medicine Market Segmentation by Region
8.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region
8.1.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region
8.1.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region
8.2 North America
8.2.1 North America Radiopharmaceuticals in Nuclear Medicine Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Radiopharmaceuticals in Nuclear Medicine Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Bracco Imaging S.P.A.
9.1.1 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.1.2 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.1.3 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.1.4 Bracco Imaging S.P.A. Business Overview
9.1.5 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine SWOT Analysis
9.1.6 Bracco Imaging S.P.A. Recent Developments
9.2 Cambridge Isotope Laboratories, Inc.
9.2.1 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.2.2 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.2.3 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.2.4 Cambridge Isotope Laboratories, Inc. Business Overview
9.2.5 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine SWOT Analysis
9.2.6 Cambridge Isotope Laboratories, Inc. Recent Developments
9.3 Cardinal Health, Inc.
9.3.1 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.3.2 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.3.3 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.3.4 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine SWOT Analysis
9.3.5 Cardinal Health, Inc. Business Overview
9.3.6 Cardinal Health, Inc. Recent Developments
9.4 Covidien, Plc
9.4.1 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Basic Information
9.4.2 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Product Overview
9.4.3 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.4.4 Covidien, Plc Business Overview
9.4.5 Covidien, Plc Recent Developments
9.5 Eczacibasi-Monrol
9.5.1 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Basic Information
9.5.2 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Product Overview
9.5.3 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.5.4 Eczacibasi-Monrol Business Overview
9.5.5 Eczacibasi-Monrol Recent Developments
9.6 Fujifilm Holdings Corporation
9.6.1 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Basic Information
9.6.2 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Product Overview
9.6.3 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.6.4 Fujifilm Holdings Corporation Business Overview
9.6.5 Fujifilm Holdings Corporation Recent Developments
9.7 GE Healthcare (Subsidiary Of General Electric Company)
9.7.1 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Basic Information
9.7.2 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Product Overview
9.7.3 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.7.4 GE Healthcare (Subsidiary Of General Electric Company) Business Overview
9.7.5 GE Healthcare (Subsidiary Of General Electric Company) Recent Developments
9.8 IBA Group
9.8.1 IBA Group Radiopharmaceuticals in Nuclear Medicine Basic Information
9.8.2 IBA Group Radiopharmaceuticals in Nuclear Medicine Product Overview
9.8.3 IBA Group Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.8.4 IBA Group Business Overview
9.8.5 IBA Group Recent Developments
9.9 Isotec, Inc. (Sigma-Aldrich)
9.9.1 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Basic Information
9.9.2 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Product Overview
9.9.3 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.9.4 Isotec, Inc. (Sigma-Aldrich) Business Overview
9.9.5 Isotec, Inc. (Sigma-Aldrich) Recent Developments
9.10 Lantheus Medical Imaging, Inc.
9.10.1 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.10.2 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.10.3 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.10.4 Lantheus Medical Imaging, Inc. Business Overview
9.10.5 Lantheus Medical Imaging, Inc. Recent Developments
9.11 Nordion, Inc.
9.11.1 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.11.2 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.11.3 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.11.4 Nordion, Inc. Business Overview
9.11.5 Nordion, Inc. Recent Developments
9.12 Ntp Radioisotopes (Pty), Ltd.
9.12.1 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.12.2 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.12.3 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.12.4 Ntp Radioisotopes (Pty), Ltd. Business Overview
9.12.5 Ntp Radioisotopes (Pty), Ltd. Recent Developments
9.13 Siemens Healthcare (Subsidiary Of Siemens AG)
9.13.1 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Basic Information
9.13.2 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Product Overview
9.13.3 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.13.4 Siemens Healthcare (Subsidiary Of Siemens AG) Business Overview
9.13.5 Siemens Healthcare (Subsidiary Of Siemens AG) Recent Developments
9.14 Taiyo Nippon Sanso Corporation
9.14.1 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Basic Information
9.14.2 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Product Overview
9.14.3 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.14.4 Taiyo Nippon Sanso Corporation Business Overview
9.14.5 Taiyo Nippon Sanso Corporation Recent Developments
9.15 Urenco Limited
9.15.1 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Basic Information
9.15.2 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Product Overview
9.15.3 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.15.4 Urenco Limited Business Overview
9.15.5 Urenco Limited Recent Developments
9.16 Rotem Industries, Ltd., Inc.
9.16.1 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.16.2 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.16.3 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.16.4 Rotem Industries, Ltd., Inc. Business Overview
9.16.5 Rotem Industries, Ltd., Inc. Recent Developments
9.17 Australian Nuclear Association And Technology Organization (ANSTO)
9.17.1 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Basic Information
9.17.2 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Product Overview
9.17.3 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.17.4 Australian Nuclear Association And Technology Organization (ANSTO) Business Overview
9.17.5 Australian Nuclear Association And Technology Organization (ANSTO) Recent Developments
9.18 Board of Radiation And Isotope Technology (BRIT)
9.18.1 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Basic Information
9.18.2 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Product Overview
9.18.3 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.18.4 Board of Radiation And Isotope Technology (BRIT) Business Overview
9.18.5 Board of Radiation And Isotope Technology (BRIT) Recent Developments
9.19 Institute of Atomic Energy Polatom Radioisotope Centre
9.19.1 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Basic Information
9.19.2 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Product Overview
9.19.3 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.19.4 Institute of Atomic Energy Polatom Radioisotope Centre Business Overview
9.19.5 Institute of Atomic Energy Polatom Radioisotope Centre Recent Developments
9.20 Institute of Isotopes Co., Ltd.
9.20.1 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Basic Information
9.20.2 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Product Overview
9.20.3 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.20.4 Institute of Isotopes Co., Ltd. Business Overview
9.20.5 Institute of Isotopes Co., Ltd. Recent Developments
9.21 Institute Of Radioelement (IRE)
9.21.1 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Basic Information
9.21.2 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Product Overview
9.21.3 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Product Market Performance
9.21.4 Institute Of Radioelement (IRE) Business Overview
9.21.5 Institute Of Radioelement (IRE) Recent Developments
10 Radiopharmaceuticals in Nuclear Medicine Market Forecast by Region
10.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size Forecast
10.2 Global Radiopharmaceuticals in Nuclear Medicine Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Country
10.2.3 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Region
10.2.4 South America Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Radiopharmaceuticals in Nuclear Medicine Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Radiopharmaceuticals in Nuclear Medicine by Type (2025-2030)
11.1.2 Global Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Radiopharmaceuticals in Nuclear Medicine by Type (2025-2030)
11.2 Global Radiopharmaceuticals in Nuclear Medicine Market Forecast by Application (2025-2030)
11.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales (Kilotons) Forecast by Application
11.2.2 Global Radiopharmaceuticals in Nuclear Medicine Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings